Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase

被引:106
作者
Du, QH
Wang, SQ
Wei, DQ [1 ]
Sirois, S
Chou, KC
机构
[1] Tianjin Normal Univ, Tianjin Inst Bioinformat & Drug Design, Tianjin 300074, Peoples R China
[2] Concordia Univ, Ctr Res Mol Modeling, Montreal, PQ, Canada
[3] Univ Quebec, Dept Chim, Montreal, PQ H3C 3P8, Canada
[4] McGill Univ, Ctr Hlth, Montreal Gen Hosp, Immune Deficiency Treatment Ctr, Montreal, PQ H36 1A4, Canada
[5] Gordon Life Sci Inst, San Diego, CA 92130 USA
基金
中国国家自然科学基金;
关键词
SARS; SARS CoV M-pro; inhibitor; drug design; Distorted key" theory;
D O I
10.1016/j.ab.2004.10.003
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Severe acute respiratory syndrome (SARS) is a respiratory disease caused by a newly found virus, called SARS coronavirus. In this study, the cleavage mechanism of the SARS coronavirus main proteinase (M-pro or 3CL(pro)) on the octapeptide NH2-AVLQ down arrow SGFR-COOH was investigated using molecular mechanics and quantum mechanics simulations based on the experimental structure of the proteinase. It has been observed that the catalytic dyad (His-41/Cys-145) site between domains 1 and 11 attracts the pi electron density from the peptide bond Gln-Ser, increasing the positive charge on C(CO) of Gln and the negative charge on N(NH) of Ser, so as to weaken the Gln-Ser peptide bond. The catalytic functional group is the imidazole group of His-41 and the S in Cys-145. N-delta1 on the imidazole ring plays the acid-base catalytic role. Based on the "distorted key theory" [K.C. Chou, Anal. Biochem. 233 (1996) 1-14], the possibility to convert the octapeptide to a competent inhibitor has been studied. It has been found that the chemical bond between Gln and Set will become much stronger and no longer cleavable by the SARS enzyme after either changing the carbonyl group CO of Gln to CH2 or CF2 or changing the NH of Ser to CH2 or CF2. The octapeptide thus modified might become an effective inhibitor or a potential drug candidate against SARS. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:262 / 270
页数:9
相关论文
共 30 条
[1]
Converting a peptide into a drug: Strategies to improve stability and bioavailability [J].
Adessi, C ;
Soto, C .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :963-978
[2]
Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].
Anand, K ;
Ziebuhr, J ;
Wadhwani, P ;
Mesters, JR ;
Hilgenfeld, R .
SCIENCE, 2003, 300 (5626) :1763-1767
[3]
*CHEM COMP GROUP I, 2004, MOE MOL OP ENV
[4]
ZCURVE_CoV: a new system to recognize protein coding genes in coronavirus genomes, and its applications in analyzing SARS-CoV genomes [J].
Chen, LL ;
Ou, HY ;
Zhang, R ;
Zhang, CT .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 307 (02) :382-388
[5]
Solution structure of BID, an intracellular amplifier of apoptotic signaling [J].
Chou, JJ ;
Li, HL ;
Salvesen, GS ;
Yuan, JY ;
Wagner, G .
CELL, 1999, 96 (05) :615-624
[6]
Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment [J].
Chou, JJ ;
Matsuo, H ;
Duan, H ;
Wagner, G .
CELL, 1998, 94 (02) :171-180
[7]
Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS [J].
Chou, KC ;
Wei, DQ ;
Zhong, WZ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 308 (01) :148-151
[9]
Prediction of human immunodeficiency virus protease cleavage sites in proteins [J].
Chou, KC .
ANALYTICAL BIOCHEMISTRY, 1996, 233 (01) :1-14
[10]
Prediction of the tertiary structure and substrate binding site of caspase-8 [J].
Chou, KC ;
Jones, D ;
Heinrikson, RL .
FEBS LETTERS, 1997, 419 (01) :49-54